0.00
price down icon100.00%   -4.97
after-market Dopo l'orario di chiusura: 4.99 4.99 +
loading
Precedente Chiudi:
$4.97
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$48.77M
Reddito:
$21.73M
Utile/perdita netta:
$-91.17M
Rapporto P/E:
0.00
EPS:
-0.74
Flusso di cassa netto:
$-286.43M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
Value
$0.00
$0.00
Intervallo di 1 settimana:
Value
$0.00
$0.00
Portata 52W:
Value
$0.00
$15.40

Bluebird Bio Inc Stock (BLUE) Company Profile

Name
Nome
Bluebird Bio Inc
Name
Telefono
339-499-9300
Name
Indirizzo
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Name
Dipendente
375
Name
Cinguettio
@bluebirdbio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
BLUE's Discussions on Twitter

Confronta BLUE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BLUE
Bluebird Bio Inc
0.00 48.77M 21.73M -91.17M -286.43M -0.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.81 104.76B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.67 63.06B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
578.05 60.32B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
843.66 51.55B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.76 34.49B 398.11M -1.03B -868.57M -5.7032

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-24 Aggiornamento JP Morgan Underweight → Neutral
2024-11-15 Downgrade BofA Securities Buy → Neutral
2024-11-15 Downgrade JP Morgan Neutral → Underweight
2024-08-15 Downgrade JP Morgan Overweight → Neutral
2023-12-11 Downgrade HSBC Securities Hold → Reduce
2023-12-08 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-10-17 Iniziato Cantor Fitzgerald Neutral
2023-09-06 Iniziato HSBC Securities Buy
2023-07-19 Aggiornamento BofA Securities Neutral → Buy
2023-06-01 Aggiornamento Barclays Equal Weight → Overweight
2023-04-28 Iniziato JP Morgan Overweight
2023-03-07 Iniziato Robert W. Baird Outperform
2022-08-05 Aggiornamento Barclays Underweight → Equal Weight
2022-08-02 Aggiornamento Raymond James Mkt Perform → Outperform
2022-04-06 Downgrade Cowen Outperform → Market Perform
2022-03-07 Downgrade Barclays Equal Weight → Underweight
2021-11-08 Reiterato Barclays Equal Weight
2021-11-08 Reiterato Canaccord Genuity Hold
2021-11-08 Downgrade Goldman Neutral → Sell
2021-11-08 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-11-08 Reiterato RBC Capital Mkts Sector Perform
2021-11-08 Reiterato Wedbush Neutral
2021-11-08 Reiterato Wells Fargo Equal Weight
2021-08-10 Downgrade Canaccord Genuity Buy → Hold
2021-08-10 Downgrade Goldman Buy → Neutral
2021-08-10 Downgrade Wells Fargo Overweight → Equal Weight
2021-08-10 Ripresa William Blair Mkt Perform
2021-08-09 Downgrade SVB Leerink Outperform → Mkt Perform
2021-07-01 Downgrade Berenberg Buy → Hold
2021-03-10 Aggiornamento Mizuho Neutral → Buy
2021-02-17 Downgrade JP Morgan Overweight → Neutral
2021-02-16 Downgrade BofA Securities Buy → Neutral
2021-02-16 Downgrade Wedbush Outperform → Neutral
2021-02-16 Downgrade William Blair Outperform → Mkt Perform
2020-12-09 Downgrade Maxim Group Buy → Hold
2020-11-11 Iniziato Berenberg Buy
2020-11-05 Downgrade BMO Capital Markets Outperform → Market Perform
2020-11-05 Downgrade Barclays Overweight → Equal Weight
2020-11-05 Downgrade Stifel Buy → Hold
2020-11-02 Aggiornamento William Blair Mkt Perform → Outperform
2020-10-20 Iniziato Mizuho Buy
2020-05-13 Iniziato RBC Capital Mkts Outperform
2020-03-27 Aggiornamento Stifel Hold → Buy
2020-02-19 Downgrade Raymond James Outperform → Mkt Perform
2020-02-03 Ripresa BofA/Merrill Buy
2020-02-03 Aggiornamento Evercore ISI In-line → Outperform
2019-12-13 Aggiornamento Oppenheimer Perform → Outperform
2019-11-26 Aggiornamento SVB Leerink Mkt Perform → Outperform
2019-11-19 Downgrade Evercore ISI Outperform → In-line
2019-11-04 Aggiornamento Wedbush Neutral → Outperform
2019-10-01 Iniziato Stifel Hold
2019-08-12 Downgrade William Blair Outperform → Mkt Perform
2019-06-18 Aggiornamento Maxim Group Hold → Buy
Mostra tutto

Bluebird Bio Inc Borsa (BLUE) Ultime notizie

pulisher
06:29 AM

Will earnings trigger a reversal in bluebird bio Inc.Quarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com

06:29 AM
pulisher
04:24 AM

Will bluebird bio Inc. see short term momentumWeekly Profit Analysis & Breakout Confirmation Alerts - newser.com

04:24 AM
pulisher
Oct 18, 2025

Should I hold or sell bluebird bio Inc. stock in 20252025 Volatility Report & Target Return Focused Stock Picks - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

What Wall Street predicts for bluebird bio Inc. stock priceAnalyst Upgrade & AI Based Buy and Sell Signals - newser.com

Oct 18, 2025
pulisher
Oct 17, 2025

Is bluebird bio Inc. stock a smart buy before Fed meetingJuly 2025 Market Mood & Detailed Earnings Play Strategies - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 16, 2025

What technical signals suggest for bluebird bio Inc. stockJuly 2025 Retail & Daily Chart Pattern Signals - newser.com

Oct 16, 2025
pulisher
Oct 16, 2025

Lobbying Update: $60,000 of GENETIX BIOTHERAPEUTICS INC. (FORMERLY BLUEBIRD BIO INC.) lobbying was just disclosed - Quiver Quantitative

Oct 16, 2025
pulisher
Oct 15, 2025

Is bluebird bio Inc. stock supported by strong fundamentalsWeekly Risk Report & Entry Point Confirmation Signals - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Car T Cell Therapy For Multiple Myeloma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary - Barchart.com

Oct 14, 2025
pulisher
Oct 14, 2025

United States Adrenoleukodystrophy Treatment Market - openPR.com

Oct 14, 2025
pulisher
Oct 13, 2025

Pattern recognition hints at bluebird bio Inc. upsideMarket Sentiment Summary & Daily Price Action Insights - newser.com

Oct 13, 2025
pulisher
Oct 11, 2025

The commercial real estate media source. - NEREJ

Oct 11, 2025
pulisher
Oct 10, 2025

Regeneron backs bluebird with $100 mn, jointly work on cancer therapies - Entrepreneur India

Oct 10, 2025
pulisher
Oct 10, 2025

Has bluebird bio Inc. formed a bullish divergenceJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Analyzing recovery setups for bluebird bio Inc. investorsWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

News impact scoring models applied to bluebird bio Inc.Market Sentiment Summary & Technical Entry and Exit Tips - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Will bluebird bio Inc. benefit from macro trendsWeekly Trade Report & Technical Confirmation Trade Alerts - newser.com

Oct 09, 2025
pulisher
Oct 06, 2025

Will bluebird bio Inc. bounce back from current supportDay Trade & Low Risk Investment Opportunities - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Is bluebird bio Inc a good long term investmentRisk Management Strategies & Free Explosive Wealth Accumulation - earlytimes.in

Oct 05, 2025
pulisher
Oct 05, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio LawsuitBLUE - MarketScreener

Oct 05, 2025
pulisher
Oct 05, 2025

Chart based analysis of bluebird bio Inc. trends2025 Sector Review & Low Risk High Reward Ideas - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Is bluebird bio Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com

Oct 03, 2025
pulisher
Oct 01, 2025

Former bluebird CEO picked to lead Inventiva - biocentury.com

Oct 01, 2025
pulisher
Sep 30, 2025

What’s the recovery path for long term holders of bluebird bio Inc.Weekly Market Report & Low Volatility Stock Recommendations - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Gene Therapy for Rare Disease Market to Reach US$ 24.54 Bn by 2033, - openPR.com

Sep 30, 2025

Bluebird Bio Inc Azioni (BLUE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$37.01
price up icon 1.84%
$87.57
price up icon 0.30%
$33.17
price up icon 1.28%
$105.14
price up icon 0.06%
biotechnology ONC
$316.42
price down icon 0.50%
$165.76
price up icon 1.57%
Capitalizzazione:     |  Volume (24 ore):